Investigational Drug Information for BLD-2660
✉ Email this page to a colleague
What is the development status for investigational drug BLD-2660?
BLD-2660 is an investigational drug.
There have been 4 clinical trials for BLD-2660.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 4th 2020.
The most common disease conditions in clinical trials are Fibrosis, COVID-19, and Pulmonary Fibrosis. The leading clinical trial sponsors are Blade Therapeutics, Clinipace Worldwide, and [disabled in preview].
Summary for BLD-2660
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-05-04) |
| Vendors | 18 |
Recent Clinical Trials for BLD-2660
| Title | Sponsor | Phase |
|---|---|---|
| Healthy Volunteer Study Comparing Tablet and Capsule Formulations | Blade Therapeutics | Phase 1 |
| Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Clinipace Worldwide | Phase 2 |
| Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Blade Therapeutics | Phase 2 |
Clinical Trial Summary for BLD-2660
Top disease conditions for BLD-2660
Top clinical trial sponsors for BLD-2660
US Patents for BLD-2660
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
